Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Testosterone therapy can modestly improve sexual function in menopausal women but should be used cautiously and is not recommended for routine measurement in sexual dysfunction or hirsutism.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Serum triglyceride levels are not linked to prostate cancer risk.

Obese women with PCOS have lower vitamin D levels.

Finasteride lowers PSA levels and prostate size, requiring adjusted PSA interpretation for accurate cancer screening.

Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Testosterone may help increase sexual events for women with low libido due to antidepressants.

Testosterone can slow down hair growth when combined with certain cells from bald scalps, and this effect can be blocked by an androgen receptor blocker.

Finasteride doesn't affect hormone levels in normal men.

A 5 mg dose of transdermal testosterone cream effectively restores testosterone levels in postmenopausal women.

Postmenopausal women with hyperandrogenism didn't have better metabolic health even after their testosterone levels became normal.

Testosterone treatment can improve sexual function and bone density in women but may have adverse effects and requires more research on safety and guidelines.

High testosterone levels in 20% of the women studied may indicate PCOS, while 80% had low levels with potential health impacts.

Higher androgen levels are linked to more severe hair growth in hirsute women.

Women with PCOS have higher irisin levels, which may affect their metabolism and hormones.

Adolescent females with PCOS have higher serum cystatin C levels, indicating potential metabolic and cardiovascular issues.

Men with Type 2 Diabetes have lower DHT levels, which may affect fertility and lipid profiles.

High testosterone increases heart disease risk in women with PCOS.

High testosterone to epitestosterone ratio in hair could predict male-pattern baldness.

Some women with acne have higher levels of free testosterone, which might suggest using hormonal treatments for acne.

Hair analysis can somewhat track past testosterone levels but is influenced by factors like hair washing, growth rate, sex, and hair color.

Early onset hair loss linked to genetics and androgen levels.

Method accurately measures finasteride in tablets using finasteride-BSA interaction.

Women with acne and irregular periods had higher active testosterone levels, which could suggest the usefulness of antiandrogen treatment.

Low vitamin D levels are linked to increased risk of male pattern baldness.

Low testosterone might be a common cause of hair loss in male dogs.

Men with male pattern baldness may have a higher risk of heart disease due to increased levels of a specific lipid in their blood.

A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.